Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV

Wim Adriaensen, Bart Cuypers, Carlota F Cordero, Bewketu Mengasha, Séverine Blesson, Lieselotte Cnops, Paul M Kaye, Fabiana Alves, Ermias Diro, Johan van Griensven

Research output: Contribution to journalArticlepeer-review


BACKGROUND: Visceral leishmaniasis (VL) treatment in HIV patients very often fails and is followed by high relapse and case-fatality rates. Hence, treatment efficacy assessment is imperative but based on invasive organ aspiration for parasite detection. In the search of a less-invasive alternative and because the host immune response is pivotal for treatment outcome in immunocompromised VL patients, we studied changes in the whole blood transcriptional profile of VL-HIV patients during treatment.

METHODS: Embedded in a clinical trial in Northwest Ethiopia, RNA-Seq was performed on whole blood samples of 28 VL-HIV patients before and after completion of a 29-day treatment regimen of AmBisome or AmBisome/miltefosine. Pathway analyses were combined with a machine learning approach to establish a clinically-useful 4-gene set.

FINDINGS: Distinct signatures of differentially expressed genes between D0 and D29 were identified for patients who failed treatment and were successfully treated. Pathway analyses in the latter highlighted a downregulation of genes associated with host cellular activity and immunity, and upregulation of antimicrobial peptide activity in phagolysosomes. No signs of disease remission nor pathway enrichment were observed in treatment failure patients. Next, we identified a 4-gene pre-post signature (PRSS33, IL10, SLFN14, HRH4) that could accurately discriminate treatment outcome at end of treatment (D29), displaying an average area-under-the-ROC-curve of 0.95 (CI: 0.75-1.00).

INTERPRETATION: A simple blood-based signature thus holds significant promise to facilitate treatment efficacy monitoring and provide an alternative test-of-cure to guide patient management in VL-HIV patients.

FUNDING: Project funding was provided by the AfricoLeish project, supported by the European Union Seventh Framework Programme (EU FP7).

Original languageEnglish
Article number102748
Number of pages20
Early online date28 Apr 2020
Publication statusPublished - May 2020

Bibliographical note

Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.


  • Adult
  • Amphotericin B/therapeutic use
  • Antiprotozoal Agents/therapeutic use
  • Coinfection
  • Endoribonucleases/blood
  • Female
  • Gene Expression Regulation
  • HIV/pathogenicity
  • HIV Infections/virology
  • Host-Pathogen Interactions/genetics
  • Humans
  • Interleukin-10/blood
  • Leishmania donovani/drug effects
  • Leishmaniasis, Visceral/drug therapy
  • Male
  • Phagosomes/metabolism
  • Phosphorylcholine/analogs & derivatives
  • Receptors, Histamine H4/blood
  • Recurrence
  • Serine Proteases/blood
  • Transcriptome
  • Treatment Failure

Cite this